Another study by Xuan et al. assessed sorafenib in an open-label, phase 3 setting, where patients with FLT3-ITD AML were assigned sorafenib maintenance versus non-maintenance at 30–60 days after transplantation. The gene discussed is FLT3; the disease is acute myeloid leukemia.